| Name | Title | Contact Details |
|---|
annual reviews is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HelixVM is a cutting-edge digital health start-up revolutionizing the way healthcare is delivered. Our goal is to free both physicians and patients from the repetitive and time-consuming aspects of routine care, while simultaneously increasing patient access to care and physician income. We understand that the largest healthcare issue today is the challenge of increasing capacity without increasing providers. That`s why we`ve developed innovative solutions that utilize technology to streamline the treatment process and optimize resource allocation. By harnessing the power of asynchronous medicine and AI, we are able to provide patients with fast and efficient access to care, while also freeing up physician time to focus on more complex and critical cases. At HelixVM, we believe that by empowering patients and providers with the tools they need to deliver and receive high-quality care, we can help to transform the healthcare industry. Whether you`re a physician looking for a more efficient and rewarding way to practice medicine, or a patient seeking convenient and accessible care, we are here to help. Join us on our mission to revolutionize healthcare delivery and improve patient outcomes.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Kerby Centre is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stanford Health Care, with multiple facilities throughout the Bay Area, is internationally renowned for leading edge and coordinated care in cancer care, neurosciences, cardiovascular medicine, surgery, organ transplant, medicine specialties, and primary care. Throughout its history, Stanford has been at the forefront of discovery and innovation, as researchers and clinicians work together to improve health, alleviate suffering, and translate medical breakthroughs into better ways to deliver patient care. Stanford Health Care: Healing humanity through science and compassion, one patient at a time. At Stanford Health Care, your career is supported within a distinctive hospital culture. This environment compliments the pioneering, collaborative atmosphere that has earned us our worldwide reputation for excellence.